This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View
by Zacks Equity Research
QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.
QuidelOrtho (QDEL) Q2 Earnings Miss Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of -42.55% and 7.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.
Stryker's (SYK) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus on laboratory workflow productivity, quality control, and new opportunities in molecular diagnostics.
Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Lantheus Holdings, Inc. (LNTH) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
LabCorp's (LH) Diagnostics base business organic volume is anticipated to have continued its rally in Q2, led by consistent growth in esoteric and routine procedures.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Strong Invisalign adoption and continued growth in the iTero scanner installed base are likely to have driven Align Technology's (ALGN) Q2 performance.
What's in Store for Thermo Fisher (TMO) in Q2 Earnings?
by Zacks Equity Research
The emergence of the new virus variants, through the months of Q2, is likely to have led to top-line contributions within Thermo Fisher's (TMO) Life-Science Solutions segment.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) Q3 results will likely gain from the continued uptake of its Panther instruments and an ongoing rebound in elective procedures.
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
by Zacks Equity Research
Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q2 on the continuous rollout of Alinity.
OrganiGram (OGI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrganiGram (OGI) delivered earnings and revenue surprises of -50% and 5.67%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) to Report Q2 Earnings: What's In Store?
by Zacks Equity Research
Quest Diagnostics (DGX) second-quarter 2022 results will likely have gained from an ongoing rebound in the base business.
Can QuidelOrtho (QDEL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Add QuidelOrtho (QDEL) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Walgreens Boots (WBA) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Walgreens Boots (WBA) reports better-than-expected Q3 earnings, with robust sales contributions from the International and Walgreens Health segments.
Zacks.com featured highlights include Boyd Gaming, Lithia Motors, Everest Re Group, Jones Lang LaSalle and QuidelOrtho
by Zacks Equity Research
Boyd Gaming, Lithia Motors, Everest Re Group, Jones Lang LaSalle and QuidelOrtho are part of Zacks Screen of the week article.
5 Stocks With Robust Sales Growth to Beat Recession Woes
by Swayta Shah
Steady sales growth is the key to survival for a business, even during recessions. Let's check at Boyd Gaming (BYD), Lithia Motors (LAD), Everest Re (RE), Jones Lang LaSalle (JLL) & QuidelOrtho (QDEL) that are recording top-line growth.
Is the Options Market Predicting a Spike in QuidelOrtho (QDEL) Stock?
by Zacks Equity Research
Investors need to pay close attention to QuidelOrtho (QDEL) stock based on the movements in the options market lately.
Is QuidelOrtho (QDEL) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
QuidelOrtho (QDEL) Stock Jumps 3.9%: Will It Continue to Soar?
by Zacks Equity Research
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Quidel (QDEL) Down 9.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Quidel (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.